New Olympus OEV321UH Monitor Brings Value, Expansion of 4K Offering and a Range of Compatibility Options for Endoscopy and Surgical Suites

Olympus announced today the availability of a new monitor option, the OEV321UH video display monitor, a 32-inch Ultra High Definition 4K monitor that expands upon Olympus 4K monitor offerings. Backward- and forward-compatible with most Olympus processors, the new monitor provides a breadth of customizable uses at an attractive price point.

“With this new OEV321UH Monitor, customers can upgrade their endoscopy suites and ORs to have larger screens that will be important to their practices for a range of cases,” said Kevin Mancini, Business Unit Vice President, Endoscopy Division, Olympus America, Inc. “Visualization improvements can translate into meaningful practice improvements that elevate the standard of care.”

The OEV321UH video monitor features includei:

  • Design compatible with future systems, including 12G-SDI connections for single cable 4K routing;
  • A 32-inch screen for a larger viewing area, following an observed customer trendii
  • Compatibility with a range of endoscopy and surgical systems;
  • Fully adjustable design to address specific viewing needs;
  • CLONE OUT function, which is used to duplicate the main monitor’s HD/4K display for use on a second monitor or on a recording device, including PIP/POP (picture-in-picture/picture-out-picture) display;
  • Split screen functionality and compatibility with telecollaboration tools;
  • Advanced Image Multiple Enhancer (A.I.M.E.) for sharp, vivid image of structures without increasing noise: creates enhanced texture that supports more detailed observation;
  • Flat display and detachable cable cover for quick and easy monitor cleaning; access window in cable cover also allows for convenient cable routing.

Since its development of the first flexible gastroscope in 1950, Olympus has continued to bring new endoscopy and surgical innovations to market, while also delivering excellent service, support and ongoing training toward workflow optimization and operational efficiency. Olympus products and services meet a range of procedural needs, which means customers have the tools they need to stay at the forefront of their fields, as they work to help patients live longer, healthier lives.

For more information about the OEV321UH, visit here.

i Data on file with Olympus (DC00675762).

ii https://www.aorn.org/outpatient-surgery/articles/outpatient-surgery-magazine/2017/february/does-size-matter-when-it-comes-to-surgical-displays

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.